<DOC>
	<DOCNO>NCT02563522</DOCNO>
	<brief_summary>This study ass safety efficacy use gene therapy via intramuscular injection calf patient chronic non-healing foot ulcer .</brief_summary>
	<brief_title>Safety Efficacy Study VM202 Treatment Chronic Non-Healing Foot Ulcers</brief_title>
	<detailed_description>A phase III , randomize , double-blind , placebo-controlled , multicenter , 7-month study design ass safety efficacy intramuscular ( IM ) injection calf VM202 patient chronic nonhealing foot ulcer . Three hundred patient randomize 2:1 ratio VM202 placebo injection : - Active -VM202 + standard care - 200 patient - Control - Placebo ( VM202 Vehicle ) + standard care - 100 patient</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>Documented symptomatic PAD , one follow criterion satisfy : ABI &gt; 0.40 ≤ 0.90 ( i.e. , mild severe PAD without critical limb ischemia ) target limb TBI ≤ 0.7 target limb Toe pressure &lt; 55 mm Hg target limb A history intermittent claudication previous relate intervention leg Documented history Type I II diabetes current treatment control ( HbA1c ≤ 12.0 % Screening ) currently oral medication / insulin No significant change anticipate diabetes medication regimen At Screening , subject one ulcer target foot fulfills follow criterion : Present ≥ 2 week ≤1 year Full thickness involve bone , tendon , capsule ( probe tendon capsule ) No sign infection osteomyelitis Ulcer must 0.5 cm2 6.5 cm2 measure Screening Visit prior debridement Subjects undergo protocoldefined standardize wound care screen ( two week longer ) . Subjects consider screen failure receive study injection Day 0 ( baseline ) target ulcer meet entry criterion ( see ) well confirm nonhealing . Be capable understand comply protocol signing informed consent document prior subject study relate procedure If female childbearing potential , negative urine pregnancy test screen use acceptable method birth control study . Will require revascularization target leg within 3 month randomization ; Unhealed prior amputation ; In investigator 's assessment , require amputation target leg within 3 month randomization ; Subject diagnose critical limb ischemia ( CLI ; Rutherford score ≥ 4 ) ; Subjects target foot ulcer etiology vasculitis , pyoderma gangrenosum , necrobiosis lipoidica , hydrostatic pressure/venous insufficiency , neoplasm ( basalioma , Kaposi 's sarcoma , squamous cell carcinoma , etc . ) , due burn ; More one ( 1 ) ulcer target foot ; The study ulcer increase 50 % baseline screening , , opinion investigator , increase due patient noncompliance wound care instruction due mitigate factor may interfere interpretation study result ; Evidence active infection ( e.g. , cellulitis , osteomyelitis ) deep ulceration expose bone tendon foot plan treatment ; Any gangrene ; Current fracture target foot ; Target ulcer locate Charcot foot ; Heart Failure New York Heart Association ( NYHA ) classification III IV ; Body mass index ( BMI ) &gt; 35 kg/m2 Screening ; Stroke myocardial infarction within last 3 month ; Unstable angina ; Uncontrolled hypertension define sustain systolic blood pressure ( SBP ) &gt; 200 mmHg diastolic BP ( DBP ) &gt; 110 mmHg baseline/screening evaluation ; Ophthalmologic condition pertinent proliferative retinopathy condition preclude standard ophthalmologic examination ; Inflammatory disorder blood vessel ( inflammatory angiopathy , Buerger 's disease ) ; Subjects advance liver disease include decompensated cirrhosis , jaundice , ascites bleed varix ; Subjects currently receive immunosuppressive medication chemotherapy , radiation therapy ; Positive HIV AntiHuman TCell Lymphotropic Virus ( HTLV ) Screening ; Active Hepatitis B C infection determine Hepatitis B surface antibody ( HBsAb ) , Hepatitis B core antibody ( IgG [ immunoglobulin M ] IgM ; HBcAb ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( AntiHCV ) , Screening ; Specific laboratory value screen include : Hemoglobin &lt; 8.0 g/dL , white blood cell count ( WBC ) &lt; 3,000 cell per microliter , platelet count &lt; 75,000/mm3 , aspartate aminotransferase ( AST ) and/or aspartate aminotransferase ( ALT ) &gt; 3 time upper limit normal clinically significant lab abnormality opinion investigator exclusionary ; Glomerular filtration rate ( GFR ) ≤ 30 mL/min/1.73 m2 Patients recent history ( &lt; 5 year ) new screen find malignant neoplasm except basal cell carcinoma squamous cell carcinoma skin ( excised evidence recurrence least 1 year ) ; patient family history colon cancer first degree relative exclude unless undergone colonoscopy last 12 month negative finding ; Subjects comorbid condition likely interfere assessment safety efficacy estimate life expectancy le 1 year ; Subjects require &gt; 81 mg daily acetylsalicylic acid . If &gt; 81 mg take screening , subject may enrol willing/able switch another medication duration study ; Subjects require regular ( daily ) COX2 inhibitor drug ( ) high dose steroid ( except inhale steroid ocular steroid ) ; subject may enrol willing/able undergo medication washout prior first dose refrain take drug study ; Major psychiatric disorder past 6 month ; History drug alcohol abuse / dependence past 2 year ; Use investigational drug past 3 month ; use investigational biologic past 12 month ; concurrent participation investigational protocol unapproved therapeutic ; Unable unwilling give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>non heal ulcer</keyword>
	<keyword>VM202</keyword>
	<keyword>Diabetic ulcer</keyword>
	<keyword>foot ulcer</keyword>
</DOC>